Paul Hartnett has served as HHRA’s CFO since our founding . Paul has now joined the board as Treasurer and Executive Director.

July 19, 2024 – In June of this year, the Heartland Study achieved a major milestone, enrolling its 1,000th mother-infant pair. Enrollment is now at 50% of goal. The objective of the Study is to help fill major gaps in our understanding of the impacts of herbicides on maternal and infant health. Currently in Phase 1, the Study is focused on evaluating associations between herbicide concentrations in body fluids and tissue samples from pregnant women and infants, and pregnancy/childbirth outcomes. Phase 2 is designed to evaluate potential associations between herbicide biomarkers and early childhood neurological development. Much appreciation for the mothers enrolled, and the entire Heartland Study Team including scientists, support staff and clinicians for this tremendous achievement, and for our funders to making this work possible. Read more about the study including peer-reviewed studies published in Chemosphere and Agrichemicals at our publications  page. The investment required to conduct this study exceeds $1 million each year. You can support this important work by making a donation here.

Last year was a year of progress for the HHRA and the Heartland Study. Read about it here!  

An increasingly popular way to manage charitable giving is by donating cash, securities, or other assets into a donor-advised fund (DAF), from which you will receive an immediate tax deduction. From this, donors can recommend grants to IRS-qualified nonprofit organizations.  DAFs are one of the easiest and most tax-advantageous ways to “grow” resources earmarked for future charitable giving.  The HHRA is an IRS-qualified organization, and we encourage you to use your DAF, if you have one, to support our mission. You can find three simple steps to supporting our research via your DAF here.  Simple and convenient, your DAF can have genuine effects on the health of mothers, babies, and future generations.  Thank you!

Dicamba and 2,4-D in the Urine of Pregnant Women in the Midwest: Comparison of Two Cohorts (2010–2012 vs. 2020–2022) Abstract Currently, there are no known human biomonitoring studies that concurrently examine biomarkers of dicamba and 2,4-D. We sought to compare biomarkers of exposure to herbicides in pregnant women residing in the US Midwest before and after the adoption of dicamba-tolerant soybean technology using urine specimens obtained in 2010–2012 from the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (N = 61) and in 2020–2022 from the Heartland Study (N = 91). Specific gravity-standardized concentration levels for each analyte were compared between the cohorts, assuming data are lognormal and specifying values below the LOD as left-censored. The proportion of pregnant individuals with dicamba detected above the LOD significantly increased from 28% (95% CI: 16%, 40%) in 2010–2012 to 70% (95% CI: 60%, 79%) in 2020–2022, and dicamba concentrations also significantly increased from 0.066 μg/L (95% CI: 0.042, 0.104) to 0.271 μg/L (95% CI: 0.205, 0.358). All pregnant individuals from both cohorts had 2,4-D detected. Though 2,4-D concentration levels increased, the difference was not significant (p-value = 0.226). Reliance on herbicides has drastically increased in the last ten years in the United States, and the results obtained in this study highlight the need to track exposure and impacts on adverse maternal and neonatal outcomes. Keywords: pesticide; exposure; 2,4-dichlorophenoxyacetic acid; human biomonitoring You can read the paper here.